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1. Introduction 
Recent papers have reported the usefulness of DBT as the latest diagnostic modality for 
breast cancer [1]-[6]. In this chapter, the author describes clinical evaluation of the 
usefulness regarding DBT with reference to other diagnostic modalities such as Full Field 
Digital Mammography (FFDM), contrast-enhanced (CE) MRI, contrast-enhanced (CE) CT, 
and ultrasound (US) in accordance with preliminary experiences in breast cancer 
diagnosis. 
2. Diagnostic impact of adjunction of Digital Breast Tomosynthesis (DBT)  
to Full Field Digital Mammography (FFDM) and in comparison with Full Field 
Digital Mammography (FFDM) 
Purpose: To evaluate the diagnostic impact of adjunction of DBT to FFDM and in 
comparison with FFDM only, in accordance with pathological findings and breast density. 
Materials and Methods: This study was approved by the IRB at our institute. 303 women, 
having 333 lesions, (age 29-84, mean age 54.0 years old) that were recruited for this study 
gave informed consent. The images were taken as diagnostic mammograms from October in 
2009 to October in 2011. 45 cases were referred from other institutions by US and 258 cases 
were referred by MMG or palpation. Clinical image data were acquired by an a-Se FFDM 
system with a spatial resolution of 85μm (MAMMOMAT Inspiration, Siemens, 
Germany).Two-view DBT was performed with the same rotation angle (±25°) and 
compression pressure as the FFDM. With one-view DBT, the radiation dose was 1.5 times 
compared to one-view FFDM. The radiation dose, utilizing ACR 156 phantom by FFDM, 
was 1.20mGy. Images were reconstructed by the shift and add method and the filtered back 
projection (FBP) method. FFDM and reconstructed slice images of DBT were reviewed at a 
dedicated workstation (MAMMO Report, Siemens, Germany). Two radiologists and four 
breast surgeons evaluated the findings by FFDM only and the adjunction of DBT to FFDM 
before surgery in accordance with BIRADS categories; BIRADS1-2 (no findings or benign), 
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BIRADS 3 (probably benign, but short-term follow-up or additional diagnostic procedure 
necessary), and BIRADS 4-5(highly suspicious or definitely malignant and a biopsy 
necessary). All cases were operated on and confirmed as malignant or borderline lesions 
pathologically.  
Results: 181 cases were diagnosed as fatty or scattered (BIRADS density 1-2) and 122 cases 
were diagnosed as inhomogeneous dense or dense (BIRADS density 3-4). Of the 
pathological findings, 186 lesions were diagnosed as Invasive Ductal Carcinoma(IDC), 60 
lesions were diagnosed as Ductal Carcinoma in Situ(DCIS), 33 lesions were IDC 
predominantly Ductal Carcinoma in Situ(DCIS),16 lesions were diagnosed as Invasive 
Lobular Carcinoma(ILC), 7 lesions were diagnosed as Lobular Carcinoma in Situ (LCIS), 5 
lesions each were diagnosed as Mucinous Carcinoma (Muc Ca) and Intraductal Papilloma 
(IDP), 4 lesions were diagnosed as Apocrine Carcinoma, 3 lesions each were diagnosed as 
Mixed IDC+ILC and Intracystic Papillary Tumor(ICPT), two lesions each were diagnosed as 
Invasive Micropapillary Carcinoma(IMPC), DCIS with LCIS, and Phyllodes Tumor, and one 
lesion each was diagnosed as SCC, ILC with DCIS, ILC predominantly DCIS, ILC 
predominantly LCIS, and Muc Ca predominantly DCIS (Table1.). With FFDM only, the 
detection rate was 88.9% (176/198) for breasts with BIRADS density 1-2 and 83.7% (113/135) 
for breasts with BIRADS density 3-4. The findings by FFDM only were mass (n=142; 42.6%), 
Focal Asymmetry(FA) (n=31; 9.3%), distortion (n=15; 4.5%), microcalcifications (n=40; 
12.0%), microcalcifications with FA (n=8; 2.4%), microcalcifications with distortion (n=7; 
2.1%), microcalcifications with mass (n=46; 13.8%), and none (n=44; 13.2%). 
With adjunction of DBT to FFDM, the detection rate (BIRADS 3-5) was 97.4% (193/198) for 
breasts with BIRADS density 1-2 and 94.8% (128/135) for breasts with BIRADS density 3-4. 
The average detection rate was 86.8% by FFDM only and 96.4% by adjunction of DBT to 
FFDM. There was a statistically significant difference between the FFDM only and 
adjunction of DBT to FFDM among BIRADS density 1-2 and BIRADS density 3-4 (P<0.05). 
On the other hand, there was no statistically significant difference according to breast 
density (FFDM only: P=0.221, 3-4; adjunction of DBT to FFDM: P=0.202).By BIRADS 
category with FFDM only, 44 lesions (13.2%) were diagnosed as BIRADS 1 or 2, 75 lesions 
(22.5%) were diagnosed as BIRADS 3, 214 lesions (64.3%) were diagnosed as BIRADS 4 or 5; 
on the other hand, 12 lesions (3.6%) were diagnosed as BIRADS 1 or 2, 21 lesions (6.3%) 
were diagnosed as BIRADS 3, 300 lesions (90.1%) were diagnosed as BIRADS 4 or 5 (Table 
2.,Fig1).  
In addition, regarding radiological findings, diagnostic accuracy was improved in 96 lesions 
(BIRADS 1-2 to BIRADS 3-5 or BIRADS 3 to BIRADS 4-5). These included 93 mass-related 
lesions (mass, FA, or distortion) and 3 microcalcifications-related lesions 
(microcalcifications, microcalcifications and FA, or microcalcifications and distortion). 
However, diagnostic confidence was improved in cases of microcalcifications-related lesions 
owing to the presence of masses or focal dense areas with microcalcifications. In addition, 
by adjunction of DBT to FFDM, 32 more lesions were detected in comparison with FFDM 
only (Table 3.)  
Discussion. According to recent reports, DBT is a useful diagnostic procedure compared to 
2D mammography because breast structures are superimposed onto a two-dimensional (2D) 
image [6]. The outline of the lesion can be potentially obscured. Our preliminary results also 
indicated that adjunction of DBT to FFDM contributed not only to detecting the lesion, but 
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also to clarifying the diagnostic accuracy, especially with regard to mass-related lesions. On 
the other hand, regarding microcalcifications-related lesions, only using DBT slice image, it 
is difficult to recognize the overview of the clustered microcalcifications and analyze the 
morphology of each microcalcification’s outline at current settings for image acquisition and 
reconstruction. As a result, adjunction of DBT to FFDM is the best current option. 32 more 
lesions were detected by adjunction of DBT to FFDM. Not only 14 invasive cancers (IDC 
n=11, ILC n=2, ILC pred LCIS n=1), but also 18 non-invasive cancerous or borderline lesions 
(DCIS n=15, LCIS n=1, IDP n=2). 
Adjunction of DBT to FFDM was useful to detect early stage breast cancer and it is not 
affected by breast density. 
Conclusion. In this study, the results indicated that adjunction of DBT to FFDM was 
superior to FFDM only, regarding diagnostic performance.  
 
333 Lesions 303 cases with
IDC  n=186 
DCIS  n=60
IDC Pred DCIS  n=33
ILC  n=16
LCIS  n=7
Muc Ca  n=5
IDP  n=5
Apocrine Ca  n=4
IDC with ILC  n=3
ICPT  n=3
IMPC  n=2
DCIS with LCIS n=2
Phyllodes Tumor n=2
SCC  n=1
ILC with DCIS  n=1
ILC Pred DCIS  n=1
ILC Pred LCIS  n=1
Muc Ca Pred DCIS                                       n=1                        
Total                    n=333
Table 1. Subtypes of Pathological Findings of the Lesions. 
 
FFDM only Adjunction of DBT to FFDM
BIRADS 1 or 2    n=44   BIRADS 1 or 2    n=12 
BIRADS 3      n=10 
BIRADS 4 or 5   n=22 
BIRADS 3        n=75 BIRADS 3     n=11 
BIRADS 4 or 5    n=64 
BIRADS 4 or 5    n=214  BIRADS 4 or 5     n=214 
Total n=333
Table 2. Categorical Changes of FFDM Only Vs. Adjunction of DBT to FFDM.  
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FFDM Only Adjunction of DBT to FFDM
DCIS  n=22 n=7 
IDC   n=13 n=2 
LCIS  n=3 n=2 
ILC n=2 n=0 
IDP n=2 n=0 
ILC Pred LCIS n=1 n=0 
ICPC                          n=1                  n=1          
Total n=44 n=12 
Table 3. Missed Lesions in Pathological Findings by FFDM Only Vs. Adjunction of DBT to 
FFDM. 
   
                   a. FFDM image             b. DBT image 
 
c. US image 
Fig. 1. Radiological Findings of Adjunction of DBT and US images. 
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FFDM (Fig.1a) showed distortion only in the right breast by CC view (white arrow).DBT 
(Fig.1b) showed an irregularly shaped mass corresponding to the distortion shown by 
FFDM (white arrow). US (Fig.1c) showed hypo-echoic masses corresponding to the lesion 
shown by DBT (white arrow). The pathological diagnosis was IDC (Sci Ca). 
3. Evaluation of correlation between pathological size and diagnostic size  
Purpose 
To compare the diagnostic performance between combined Full Field Digital 
Mammography (FFDM) and Digital Breast Tomosynthesis (DBT) in comparison with US 
and contrast enhanced MRI with regard to the extent of the lesion. 
Materials and methods 
This study was approved by the IRB at our institute. 196 women having 217 lesions (age 29-77, 
mean age 53.0 years old) that were recruited for this study, gave informed consent. The images 
of FFDM, DBT, US, and contrast enhanced MRI were taken for diagnosis before surgery from 
October, 2009 to October, 2011. Regarding FFDM and DBT, clinical image data were acquired 
by an a-Se FFDM system with a spatial resolution of 85μm (MAMMOMAT Inspiration, 
Siemens, Germany). Two-view DBT was performed with the same compression angle and 
compression pressure as the FFDM. With one-view DBT, the radiation dose was 1.5 times that 
of one-view FFDM. The radiation dose, utilizing ACR 156 phantom by FFDM, was 1.20mGy. 
FFDM and reconstructed slice images of DBT were reviewed at a dedicated workstation. 
Regarding contrast enhanced MRI, MIP images and MPR images (coronal, axial, sagittal) of 
3mm thickness reconstructed from dynamic MRI (four phases) at 3.0 tesla were evaluated. 
Two radiologists and three breast surgeons evaluated the findings regarding extent of the 
lesion by FFDM only, FFDM plus DBT, US, and contrast enhanced MRI in a non-blind 
consensus study before surgery, and compared the total size of the lesion with the actual 
pathological size of the lesion. The coefficient of correlation was analyzed by Pearson’s 
Product Moment Correlation Coefficient (SPSS Statistics 17.0, IBM, USA). 
Results 
Of the pathological findings, 125 lesions (57.6%) were diagnosed as IDC, 39 lesions (18.0%) 
were diagnosed as DCIS, 21 lesions (9.7%) were diagnosed as IDC predominantly DCIS, 11 
lesions (5.1%) were diagnosed as ILC, five lesions (2.3%) were diagnosed as LCIS, three 
lesions each (2.4%) were diagnosed as Muc ca and Apocrine Ca, two lesions each (0.9%) 
were diagnosed as Phyllodes Tumor and IMPC, one lesion (0.5%) each was diagnosed as 
ILC with DCIS, Mixed ILC and IDC, Muc Ca pred DCIS, and ICPC(Table1.).The sensitivity 
of the lesion was 0.908 (197/217) by MMG, 0.972(211/217) by adjunction of DBT to FFDM, 
0.927(201/217) by US, and 0.977 (212/217) by MRI.MMG missed 20 lesions (DCIS n=14, IDC 
n=5, and ICPC n=1), adjunction of DBT to FFDM missed 6 lesions ( DCIS n=5 and ICPC 
n=1), US missed 16 lesions ( DCIS n=12, IDC n=2, IDC pred DCIS n=1, and LCIS n=1) , and 
MRI missed 5 lesions (DCIS n=5). 
The coefficient of correlation between pathological diagnostic size and each modality was 
0.352 with FFDM (P<0.01), 0.586 with adjunction of DBT to FFDM (P<0.01), 0.472 with US 
(P<0.01), and 0.628 with MRI (P<0.01) regarding IDC and ILC (n=136; pathological size; 3-
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108mm, average 35.4mm), 0.516 with FFDM (P<0.05), 0.590 with adjunction of DBT to FFDM 
(p<0.01), 0.375 with US (P>0.05), and 0.688 with MRI(P<0.01) regarding IDC predominantly 
DCIS (n=21; pathological size; 14-104mm, average 46.9mm), and 0.454 with FFDM (P<0.01), 
0.589 with adjunction of DBT to FFDM (P<0.01), 0.130 with US (P>0.05), and 0.558 (P<0.01) 
with MRI regarding DCIS(n=39; pathological size; 4-100mm, average 32.6mm) (Fig.2). 
Discussion 
According to recent reports, CE-MRI is sensitive in evaluating the extent of cancerous 
lesions; on the other hand, it involves the risk of overestimation of the size of the lesion [7]. 
In this study, we evaluated the sensitivity and the tumor size determined by FFDM only, 
adjunction of DBT to FFDM, US, and MRI compared with that determined by pathological 
diagnosis. In this study, regarding the sensitivity of the lesion, MRI showed the highest 
sensitivity and adjunction of FFDM to DBT showed comparable performance as well. 
Regarding the tumor size, MRI showed the strongest correlation with that determined by 
pathological diagnosis in IDC and ILC (r = 0.628) and IDC pred DCIS (r=0.688). The tumor 
size determined by adjunction of DBT to FFDM showed the second strongest correlation 
with that determined by pathological diagnosis in IDC and ILC (r = 0.586) and IDC pred 
DCIS (r=0.590) and the strongest correlation with that determined by pathological diagnosis 
in DCIS (r=0.589). By MRI, the lesions of DCIS were over-estimated compared with 
adjunction of DBT to FFDM (Fig.2c). In addition, the coefficient of correlation between 
adjunction of DBT to FFDM and MRI showed strong correlation compared to other 
diagnostic modalities, FFDM only and US. According to the results, the adjunction of DBT 
to FFDM combined with MRI can contribute to more accurate diagnosis with regard to 
evaluation of the extent of the lesion. 
Conclusion 
In this study, the results indicated that the adjunction of FFDM to DBT was superior 
compared with US or FFDM only, with regard to sensitivity and in evaluating the extent of 
the lesion. In addition, the adjunction of FFDM to DBT showed a strong correlation with 
MRI. 
 
 196 Cases 217 Lesions  
(29-77y.o.; Averag Age 53y.o) 
IDC  n=125 
ILC  n=11 
IDC Pred DCIS n=21 
DCIS n=39 
LCIS n=5 
Muc Ca n=3 
Apocrine Ca  n=3 
Phyllodes Tumor n=2 
IMPC n=2 
ILC with DCIS n=1 
Mixed ILC and IDC  n=1 
Muc Pred DCIS n=1 
ICPC                      n=1             
Total n=217
Table 4. Subtypes of Pathological Findings of the Lesions. 
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Coefficient of Correlation  0.352**
Significant Probability P<0.001
*** FFDMDBT Pathology FFDM
Coefficient of Correlation  0.586**  0.632**
Significant Probability P<0.001 P<0.001
US Pathology FFDM FFDMDBT 
Coefficient of Correlation  0.472**  0.480**  0.583**
Significant Probability P<0.001 P<0.001    P<0.001
MRI Pathology FFDM FFDMDBT US 
Coefficient of Correlation  0.628** 0.424**  0.586**   0.660** 
Significant Probability P<0.001 P<0.001 P<0.001 P<0.001 
***FFDMDBT: Adjunction of DBT to FFDM 
a. IDC,ILC  (n=136) (Pathological Size; 3-108mm, Average 35.4mm) 
 
FFDM Pathology 
Coefficient of Correlation  0.516* 
Significant Probability 0.017 
 FFDMDBT Pathology FFDM 
Coefficient of Correlation   0.590**   0.932** 
Significant Probability 0.005 P<0.001 
US Pathology FFDM FFDMDBT 
Coefficient of Correlation  0.375   0.587**   0.589** 
Significant Probability 0.094 0.005 0.005 
MRI Pathology FFDM FFDMDBT US 
Coefficient of Correlation  0.688**  0.869**   0.909** 0.542* 
Significant Probability 0.001 P<0.001 P<0.001 0.011 
b. IDC Predominantly DCIS (n=21) (Pathological Size; 14-104mm, Average 46.9mm) 
 
FFDM Pathology 
Coefficient of Correlation  0.454** 
Significant Probability 0.004 
FFDMDBT Pathology FFDM 
Coefficient of Correlation  0.589**  0.883** 
Significant Probability P<0.001 P<0.001 
US Pathology FFDM FFDMDBT 
Coefficient of Correlation 0.130 0.202 0.272 
Significant Probability 0.431 0.217 0.094 
MRI Pathology FFDM FFDMDBT US 
Coefficient of Correlation  0.558**  0.535**  0.699** 0.266 
Significant Probability P<0.001 P<0.001 P<0.001 0.101 
* Coefficient of correlation is significant at a 5% standard 
** Coefficient of correlation is significant at a 1% standard 
c. DCIS (n=39) (Pathological Size; 4-100m, Average 32.6mm) 
 
 
Table 5. Coefficients of Correlation among Pathological Sizes and Diagnostic Sizes.  
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a. Coefficients of Correlation regarding IDC and ILC 
 
b. Coefficients of Correlation regarding IDC pred DCIS 
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c. Coefficients of Correlation regarding DCIS 
Fig. 2. Scatter diagrams of coefficients of correlation among pathological sizes and 
diagnostic sizes. 
4. Usefulness of adjunction of Digital Breast Tomosynthesis (DBT) to Full-
Field Digital Mammography (FFDM) in evaluation of pathological response 
after Neoadjuvant Chemotherapy (NAC) for breast cancer  
Purpose 
Neoadjuvant chemotherapy (NAC) is performed to reduce tumor size prior to surgery in 
women with breast cancer. The imaging methods that have been used until now to assess 
tumor response to neoadjuvant chemotherapy have serious limitations; for example, 
mammography alone cannot identify mass lesions in very dense breasts or distinguish viable 
residual lesions from the surrounding fibrous reaction after NAC [8]-[10]. Digital breast 
tomosynthesis has been only recently applied clinically and the diagnostic advantages in 
comparison to mammography have been reported on, including the fact that the slice images 
can be evaluated because tomosynthesis decreases the overlap in breast tissue [1]-[6]. In this 
study, we assessed the radiological findings and capability of DBT in adjunction to FFDM to 
predict response to chemotherapy in comparison with other diagnostic modalities. 
Materials and methods 
This study was approved by the IRB at our institute. 25 women (ages 29-73, mean age, 53.0 
years old) having 26 lesions were recruited for this study and gave informed consent. The 
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images were taken for diagnosis from December, 2009 to October, 2011. Pathological 
diagnosis was confirmed by Core Needle Biopsy (CNB) and the pathological subtypes were 
Invasive Ductal Carcinoma (n=20), Invasive Lobular Carcinoma (n=3), Invasive 
Micropapillary Carcinoma (n=2), and Mucinous Carcinoma (n=1).The clinical stages of the 
patients before NAC were II or III. All patients underwent surgery based on their response 
to NAC and residual tumor size estimated by diagnostic imaging was compared with the 
residual tumor size determined by surgical pathology. The diagnostic procedures were 
performed within one month prior to surgery. MMG and US were performed on each of the 
patients before and after NAC. Contrast-enhanced MRI was performed on 15 patients, and 
contrast-enhanced CT was performed on 10 patients both before NAC and after NAC. 
Adjunction of DBT to FFDM was performed before and after NAC in 10 out of 25 cases. In 
15 out of 25 cases, adjunction of DBT to FFDM was performed only after NAC. Whole-breast 
US was performed with an 8 MHz wide-band high-resolution transducer (aplioTM XV, 
Toshiba Medical Systems, Japan). Transverse and longitudinal scans were acquired. Breast 
MRI was performed with a 3-Tesla system (Magnetom Trio, Siemens, Germany).Patients 
were studied in the prone position with a dedicated breast surface coil. The entire breast 
was imaged once before and four times after intravenous injection of 0.1mmol of Gd-
DTPA/Kg of body weight (Magnevist; Schering, Germany). The post-processing procedures 
included digital image subtraction, Maximum Intensity Projection (MIP) and Multiplanar 
Reconstruction (MPR) by slices of 3mm thickness. Breast CT was performed with multi-
detector raw CT (MDCT) (Aquilion64, Toshiba Medical Systems, Japan). The images were 
acquired before injection an iodine contrast medium, and 60 seconds after, and 3 minutes 
after injection of the total amount of 100ml, at the rate of 3ml/second (Iopamidol 300, Bayer 
AG, Germany). The images were reconstructed as slices of 2mm thickness and evaluated. 
With regard to DBT and FFDM, clinical image data were acquired by an a-Se FFDM system 
with a spatial resolution of 85μm (MAMMOMAT Inspiration, Siemens, Germany).Two-view 
DBT was performed with the same compression angle and compression pressure as the 
FFDM. With one-view DBT, the radiation dose was 1.5 times compared to one-view FFDM. 
The radiation dose with ACR 156 was 1.2mGy with FFDM. FFDM and reconstructed 1mm 
slice images from DBT were reviewed at a dedicated workstation. Two radiologists and four 
breast surgeons evaluated the findings of each diagnostic modality before surgery. The 
clinical response to chemotherapy was classified into the following categories, based on the 
“response evaluation criteria in solid tumors” (RECIST), using the measurements obtained 
with the different imaging methods: 1) Responders: a: Complete Response (CR): no clinical 
evidence of residual tumor or b: Partial Response,  (PR), reduction in size of the tumor by 
more than 30%; 2) Non-Responders : a: Stable disease (SD): reduction in size of the tumor by 
less than 30% or b: Progressive disease (PD): increase in size of tumor or presence of new 
lesions. Pathological response to chemotherapy was classified into four categories: Grade 0 
(No Response), Grade 1(Slight Response), Grade 2 (Fair Response), and Grade 3 (Complete 
Response) [11]. 
Results 
Pathological responses of the lesions to NAC were Grade 0 (n=1), Grade 1 or Grade 2 (n=21), 
and Grade 3 (n=4).MMG findings of pathological Grade 3 were microcalcifications only 
(n=1), scar only (n=1), and microcalcifications with reduced mass lesion (n=2). Two out of 
four (50.0%) lesions demonstrated CR, and two out of four lesions demonstrated PR (50.0%). 
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Regarding the Grades 1-2 cases, lesions were diagnosed as reduced mass with or without 
microcalcifications (n=19) demonstrated  PR (19/21, 90.5%) and 2 lesions diagnosed as only 
distortion or scar demonstrated CR (2/21, 9.5%). Regarding the Grade 0 case, the lesion 
detected as an enlarged mass (n=1) was diagnosed as PD (1/1, 100.0%). Adjunction of DBT 
findings of pathological Grade 3 were microcalcifications only (n=1), Scar only (n=1), and 
microcalcifications with scar without any density (n=2) that suggest CR (Fig.1). Regarding 
pathological Grades 1-2, the lesions were detected as reduced masses with or without 
microcalcifications (n=20) that suggested 20 cases were PR (20/21, 95.2%), and 1 case of only 
distortion or scar (n=1) that suggested CR (1/21, 4.8%). Regarding the Grade 0 case, the 
lesion was detected as an enlarged mass (n=1) that suggested PD (1/1, 100.0%). US findings 
of pathological Grade 3 (n=4) were diagnosed as CR (n=2, 50.0%), SD (n=1, 25.0%) and PR 
(n=1, 25.0%). US findings of pathological Grades 1-2 (n=21) were diagnosed as PR (n=17, 
81.0%), SD (n=3, 14.3%) and CR (n=1, 4.8%). In the case of US findings of pathological Grade 
0 (n=1), the lesion was diagnosed as PD (n=1, 100.0%). MRI (n=15) findings of pathological 
Grade 3 (3 lesions) were diagnosed as CR (n=2, 66.7%) and PR (n=1, 33.3%). MRI (n=15) 
findings of pathological Grades 1-2 (11 lesions) were diagnosed as PR (n=10, 90.5%) and CR 
(n=1, 9.5%). In the case of MRI findings of Grade 0(n=1), the lesion was diagnosed as PD 
(n=1, 100.0%). CT (10 cases with 11 lesions) findings of pathological Grade 3 (n=1) were 
diagnosed as CR (n=1, 100.0%). CT findings of pathological Grades 1-2 (n=10) were 
diagnosed as PR (n=10, 100.0%). MMG only resulted in two under-diagnosed lesions (2/26, 
7.7%) and two over-diagnosed lesions (2/26, 7.7%).US resulted in one under-diagnosed 
lesion (1/26, 3.8%) and five over-diagnosed lesions (5/26, 19.2%). MRI resulted in one 
under-diagnosed lesion (1/15, 6.7%) and one over-diagnosed lesion (1/15, 6.7%) (Table1).  
Discussion 
Accurate evaluation of tumor response to NAC is necessary for optimization of preoperative 
planning. MRI and CT have recently developed the potential to assist the other traditional 
imaging methods in the evaluation of response to NAC [12]-[20]. By mammography, it is 
difficult to identify a mass lesion in dense breasts or to distinguish a viable lesion from a 
fibrous reaction owing to NAC. Using US only can result in over-diagnosis of 
chemotherapy-induced fibrosis, because in the case of a hypo-echoic lesion, it is difficult to 
differentiate between a fibrotic change induced by neoplastic change and a reduction in the 
tumor by NAC. In addition, it is difficult to measure by hand-held probe the overview of a 
large mass lesion or multi-centric lesions, such as locally advanced tumors that could be 
treated by NAC (Fig.1). On the other hand, adjunction of DBT to FFDM has potential 
diagnostic advantages. In accordance with our study, compared to FFDM only, adjunction 
of DBT to FFDM can evaluate the inside of and the outline of the lesion. Compared to US, 
adjunction of DBT to FFDM can evaluate the overview of the lesion objectively. Accurate 
evaluation of tumor response to the pharmacological treatment is fundamental for optimal 
surgical planning. CE-MRI and CE-CT have recently developed the potential to assist the 
other traditional imaging methods in the evaluation of response to chemotherapy. These are 
able to discriminate between neoplastic and fibrotic tissue, based on the rate of contrast 
media enhancement [12]-[17]. In addition, the higher sensitivity of MRI can detect non-
invasive lesions as enhanced lesions that can be over-diagnosed as residual invasive 
components (Fig.2). According to our study, compared to CE-CT or CE-MRI, with 
adjunction of DBT to FFDM, it is possible to correlate the macroscopic evaluation with the 
pathological diagnosis without utilizing a contrast medium. The combination of adjunction 
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of DBT to FFDM with other diagnostic modalities will contribute to improved diagnostic 
accuracy with regard to NAC response to locally advanced breast cancer. 
Conclusion 
The adjunction of DBT to FFDM combined with other diagnostic modalities will contribute 
to more accurate assessment of pathological response to NAC. 
      




e. US: Pre NAC 
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f. US: Post NAC 
  
g. CE-CT: Pre NAC 
  
h. CE-CT: Post NAC 
FFDM (Fig.1a-b) showed reduced masses after NAC (white arrow). 
DBT (Fig.1c-d) showed reduced masses with scar with partial density inside of the corresponding lesion 
after NAC (white arrow). 
US (Fig.1e-f) showed reduced hypo-echoic masses as suspicious residual lesions after NAC (white arrow).  
The images of CE-CT (Fig.1g-h) showed reduced small enhanced nodules as suspicious residual lesions 
after NAC (white arrow).  
Fig. 3. Pathological Grade 1 Case. 
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  a. FFDM: Pre NAC    b. FFDM: Post NAC        c. DBT: Pre NAC            d. DBT: Post NAC 
  
e. US: Pre NAC      f. US: Post NAC 
   
g. MRI: Pre NAC                                             h. MRI: Post NAC 
FFDM (Fig.2a-b) demonstrated a reduced mass with microcalcifications after NAC (white arrow). 
DBT (Fig.2c-d) demonstrated microcalcifications with scar without core density inside of the 
corresponding lesion after NAC (white arrow).  
US (Fig.2e-f) demonstrated a reduced hypo-echoic mass as a suspicious residual lesion after NAC 
(white arrow).  
The coronal image of CE-MRI (Fig.2g-h) demonstrated small enhanced nodules as a suspicious residual 
lesion after NAC (white arrow). Pathological diagnosis demonstrated residual DCIS corresponding to 
the enhanced lesions by CE-MRI. 
Fig. 4. Pathological Grade 3 Case. 
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Pathological Response  MMG  US (n=26)     
Grade 0 (n=1)  *PD: n=1(100.0%)  PD: n=1(100.0%)   
Grades 1-2 (n=21) PR: n=19(90.5%), CR: 
n=2(9.5%) 
PR: n=17(81.0%), SD: n=3(14.3%), CR: n=1(4.8%) 
Grade3 (n=4) CR: n=2(50.0%), PR: 
n=2(50.0%) 
CR: n=2(50.0%), PR: n=1(25.0%), SD: n=1(25.0%) 
Pathological Response CT (n=11) 
Grades 1-2 (n=10)  PR: n=10 (100.0%) 
Grade 3 (n=1)  CR: n=1 (100.0%)         
Pathological Response  MRI (n=15) 
Grade 0 (n=1)  PD: n=1(100.0%)                             
Grades 1-2 (n=11)   PR: n=10(90.9%), CR: n=1(9.1%)                                    
Grade 3 (n=3)   CR: n=2(66.7%), PR: n=1(33.3%)   
* The clinical response to chemotherapy was classified in accordance with RECIST. 
Table 6. Comparison of NAC Response by Diagnostic Evaluation and Pathological 
Evaluation. 
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